RetinalGenix Technologies Inc. is an ophthalmic research and development company focused on developing technologies to screen, monitor, and treat eye health disorders and systemic diseases through the eye. The company operates in the medical technology and biopharmaceutical sectors, with a mission to improve patient outcomes by enabling early detection and personalized treatment of ophthalmic and systemic conditions. Its core activities revolve around genetic testing, retinal imaging, patient data management, and pharmaceutical therapies, all designed to empower patients and clinicians with secure, actionable health information.

RetinalGenix Technologies Inc. expects to generate revenue primarily through the sale of its DNA/GPS laboratory-developed genetic testing kits, which are scheduled for commercial launch in late 2026. These tests, including the GPS oral swab test and a genetic test for identifying positive responders to wet age-related macular degeneration (AMD) treatments, will be marketed to patients and healthcare providers. The company does not anticipate generating revenue from its RetinalCam imaging device or its RetinalGenix Eye Care Anonymized AI (RECAD AI) database until their development is complete. Additionally, the company may derive future revenue from pharmaceutical therapies, such as RTG-2023 for dry AMD and RTG-2024 for Alzheimer’s syndrome dementia, pending successful clinical development and regulatory approval.

The company operates through the following segments:

• Genetic Testing: This segment focuses on developing and commercializing pharmacogenetic tests to identify biomarkers for eye and systemic diseases. RetinalGenix’s wholly owned subsidiary, DNA/GPS Inc., leads this effort, with plans to launch oral swab-based genetic tests in late 2026. These tests will enable patients to assess their genetic risk profiles for conditions such as wet AMD and share results with their physicians. The segment also includes an Institutional Review Board (IRB) study in collaboration with Pearl IRB to evaluate the genetic basis for the success or failure of intraocular injections in wet AMD patients.

• Retinal Imaging Platform: This segment involves the development of portable retinal imaging devices, including the RetinalCam, designed for in-home and remote patient monitoring. The RetinalCam is a patient-operated, non-dilating device that captures high-resolution retinal images and provides real-time communication with physicians. The company expects to launch the RetinalCam by the end of 2026 and does not anticipate requiring FDA approval for its use in screening and monitoring. Images captured by the device will be integrated into the company’s secure imaging system for patient and physician use.

• Patient Informational Database: This segment centers on the development of the RetinalGenix Eye Care Anonymized AI (RECAD AI) database, a secure, interoperable system designed to combine genetic and retinal imaging data. The database will be controlled by patients, who can securely share their anonymized health information with physicians. The RECAD AI system aims to facilitate early detection of ocular and systemic diseases, including cardiovascular conditions, diabetes, and Alzheimer’s, while enabling future research and drug development through artificial intelligence-driven analysis.

• Pharmaceutical Therapies: This segment focuses on the development of repurposed pharmaceutical products for treating eye and systemic diseases. Key candidates include RTG-2023 for dry AMD and RTG-2024 for Alzheimer’s syndrome dementia. The company is advancing these therapies through partnerships with clinical resource organizations and plans to pursue collaborations with pharmaceutical companies to support future clinical trials and commercialization.

RetinalGenix Technologies Inc. operates in a highly competitive industry characterized by rapid technological advancements and a strong emphasis on intellectual property. The company faces competition from established ophthalmic medical technology firms, academic institutions, government agencies, and public and private research organizations. Its competitive advantages lie in its integrated approach, combining genetic testing, retinal imaging, and patient-controlled data management to enable early disease detection and personalized treatment. The RetinalCam’s portability, ease of use, and real-time physician alert system differentiate it from traditional diagnostic devices, which often require specialized technicians and pupil dilation. Additionally, the company’s genetic testing platform offers faster and more cost-effective biomarker analysis compared to existing providers. However, competitors with greater financial resources, established distribution networks, and deeper expertise in regulatory approvals pose significant challenges.

The company’s customer base includes patients, healthcare providers, and research institutions. Its genetic testing kits and retinal imaging devices are designed for use by patients in home settings, as well as by clinicians in hospitals, nursing homes, community care centers, schools, pharmacies, and optical outlets. The RECAD AI database will serve patients and physicians by providing secure access to anonymized genetic and imaging data for clinical decision-making. While the filing does not specify individual customer names, the company’s products are positioned to address the needs of a broad market, including individuals with chronic diseases, pre-diabetic and diabetic patients, and those at risk for age-related macular degeneration and Alzheimer’s syndrome dementia.